CULLINAN THERAPEUTICS, INC. Retained Earnings
CULLINAN THERAPEUTICS, INC. (CGEM) had Retained Earnings of -$691.48 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$691.48M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$637.78M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$588.12M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$537.41M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$691.48M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$637.78M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$588.12M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$537.41M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$486.80M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$416.74M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$368.24M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$320.59M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$280.03M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$238.00M 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$200.86M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$177.05M 10-Q · filed 2023-11-08 |
| 2023-06-30 | -$137.87M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$105.66M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$47.70M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$20.91M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $3.89M 10-Q · filed 2022-08-10 |
| 2022-03-31 | -$171.01M 10-Q · filed 2022-05-16 |
| 2021-12-31 | -$158.91M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$126.39M 10-Q · filed 2021-11-09 |
| 2021-06-30 | -$109.05M 10-Q · filed 2021-08-10 |
| 2021-03-31 | -$93.41M 10-Q · filed 2021-05-14 |
| 2020-12-31 | -$93.34M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$64.99M 10-Q · filed 2021-11-09 |
| 2020-06-30 | -$55.13M 10-Q · filed 2021-08-10 |
| 2019-12-31 | -$41.54M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |